Douglas Swirsky
Chairman at CELLECTAR BIOSCIENCES, INC.
Net worth: 7 550 $ as of 2024-04-29
Douglas Swirsky active positions
| Companies | Position | Start | End |
|---|---|---|---|
| CELLECTAR BIOSCIENCES, INC. | Chairman | 2017-07-31 | - |
| Director/Board Member | 2017-04-06 | 2017-07-31 | |
| MAXCYTE, INC. | Comptroller/Controller/Auditor | 2023-03-26 | - |
| Director of Finance/CFO | 2023-03-26 | - |
Career history of Douglas Swirsky
Former positions of Douglas Swirsky
| Companies | Position | Start | End |
|---|---|---|---|
Aavantibio, Inc.
 Aavantibio, Inc. BiotechnologyHealth Technology Aavantibio, Inc. engages in developing gene therapies. The company was founded by Barry Byrne and Manuela Corti and is headquartered in Gainesville, FL. | Director/Board Member | 2020-04-30 | 2022-11-30 |
| Director of Finance/CFO | 2020-11-30 | 2022-11-30 | |
| President | 2020-04-30 | 2020-09-30 | |
| Treasurer | 2020-11-30 | 2022-11-30 | |
| NEUROBO PHARMACEUTICALS, INC. | Director/Board Member | 2020-08-31 | 2021-01-10 |
| Chairman | 2021-01-10 | 2022-01-13 | |
| Independent Dir/Board Member | 2020-08-31 | 2022-01-13 | |
| REXAHN PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 2018-01-01 | 2020-10-31 |
| Director/Board Member | 2018-11-13 | 2020-10-31 | |
| Chief Executive Officer | 2018-11-13 | 2020-10-31 | |
| Director of Finance/CFO | 2018-01-01 | 2020-10-31 | |
| President | 2018-01-01 | 2020-10-31 | |
| Corporate Secretary | 2018-01-01 | 2020-10-31 | |
| FIBROCELL SCIENCE, INC. | Director/Board Member | 2013-03-04 | 2016-12-18 |
| Chairman | 2016-12-18 | 2019-12-12 | |
| Independent Dir/Board Member | 2013-03-04 | 2019-12-12 | |
| PERNIX THERAPEUTICS HOLDINGS INC | Director/Board Member | 2017-11-14 | 2019-05-08 |
| Independent Dir/Board Member | 2017-11-14 | 2019-05-08 | |
| GENVEC INC | Director/Board Member | 2013-08-31 | 2017-06-15 |
| Chief Executive Officer | 2013-08-31 | 2017-06-15 | |
| Director of Finance/CFO | 2006-09-18 | 2014-12-04 | |
| President | 2013-08-31 | 2017-06-15 | |
| Corporate Secretary | 2006-09-18 | 2017-06-15 | |
| Treasurer | 2006-09-18 | 2014-12-04 | |
| POLYMEDIX, INC. | Director/Board Member | 2009-05-31 | 2013-02-28 |
| Independent Dir/Board Member | 2011-11-06 | 2013-02-28 | |
| ░░░░░░░ ░░░░░░░░ ░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ | - |
Training of Douglas Swirsky
| Boston University | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Statistics
International
| United States | 14 |
| Israel | 2 |
Operational
| Director/Board Member | 8 |
| Director of Finance/CFO | 4 |
| Independent Dir/Board Member | 4 |
Sectoral
| Health Technology | 11 |
| Consumer Services | 3 |
| Finance | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| CELLECTAR BIOSCIENCES, INC. | Health Technology |
| NEUROBO PHARMACEUTICALS, INC. | Health Technology |
| MAXCYTE, INC. | Health Technology |
| Private companies | 9 |
|---|---|
GenVec, Inc.
 GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |
Stifel, Nicolaus & Co., Inc.
 Stifel, Nicolaus & Co., Inc. Investment Banks/BrokersFinance Stifel, Nicolaus & Co., Inc. (Stifel) is a dual-registered broker-dealer and investment adviser headquartered in St. Louis, Missouri. Founded in 1890, the firm is a subsidiary of Stifel Financial Corp. (NYSE: SF), a financial service holding company. Stifel provides full-service brokerage and investment advisory services to individuals and their families, institutions and businesses, and financial advisors. | Finance |
PolyMedix, Inc.
 PolyMedix, Inc. Pharmaceuticals: MajorHealth Technology PolyMedix, Inc. engaged in developing first-in-class, small-molecule defensin-mimetics for the treatment of serious acute care conditions. The company was founded in 2002 and was headquartered in Radnor, PA. | Health Technology |
Legg Mason, Inc.
 Legg Mason, Inc. Investment ManagersFinance Legg Mason, Inc. is a holding company. It engages in the provision of investment management and related products and services to institutional and individual clients, company-sponsored mutual funds, and other investment vehicles. The company was founded in 1981 and is headquartered in Baltimore, MD. | Finance |
Fibrocell Science, Inc.
 Fibrocell Science, Inc. Pharmaceuticals: MajorHealth Technology Fibrocell Science, Inc. is an autologous cell and gene therapy company, which focuses on translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. The company was founded on December 28, 1995 and is headquartered in Exton, PA. | Health Technology |
Pernix Therapeutics Holdings, Inc.
 Pernix Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Pernix Therapeutics Holdings, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It focuses on therapeutics for diseases on central nervous system, neurology, pain, and psychiatry. Its products include treatment of migraine pain and inflammation, insomnia, and depressive disorder. It distributes products through the following brands: Treximet, Silenor, and Zohydro ER with BeadTek. The company was founded in 1996 and is headquartered in Morristown, NJ. | Health Technology |
Rexahn Pharmaceuticals, Inc.
 Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | Health Technology |
Castle Creek Biosciences, Inc.
 Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | Health Technology |
Aavantibio, Inc.
Aavantibio, Inc. BiotechnologyHealth Technology Aavantibio, Inc. engages in developing gene therapies. The company was founded by Barry Byrne and Manuela Corti and is headquartered in Gainesville, FL. | Health Technology |
- Stock Market
- Insiders
- Douglas Swirsky
- Experience